Xinyang^® Abiraterone Acetate Tablets are a highly selective CYP17 enzyme inhibitor that targets multiple sites of androgen biosynthesis throughout the body. By blocking the production of endogenous androgens, it controls the progression of prostate tumors. It is mainly used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC). It was approved as a new chemical drug of Class 4 in September 2019. As a representative of new endocrine therapies for prostate cancer, Abiraterone fundamentally blocks androgen synthesis in the testes, adrenal glands, and tumors, significantly improving patient survival. It is widely recommended as a first-line treatment in guidelines globally.